Equities

3-D Matrix Ltd

7777:TYO

3-D Matrix Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)164.00
  • Today's Change12.00 / 7.89%
  • Shares traded4.10m
  • 1 Year change-8.89%
  • Beta1.1640
Data delayed at least 20 minutes, as of Jun 10 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.

  • Revenue in JPY (TTM)3.74bn
  • Net income in JPY-1.06bn
  • Incorporated2004
  • Employees108.00
  • Location
    3-D Matrix Ltd7FKojimachi HF Bldg., 3-2-4, Koji-machiCHIYODA-KU 102-0083JapanJPN
  • Phone+81 335113440
  • Fax+81 335113402
  • Websitehttps://www.3d-matrix.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wakamoto Pharmaceutical Co Ltd7.74bn108.96m8.74bn292.0079.950.724489.441.133.143.14222.97346.510.49712.092.57--0.70-2.280.8046-2.6446.5251.001.41-3.973.85--0.0083---10.65-6.35-21.19--4.93--
Kohjin Bio Co Ltd4.77bn384.98m8.75bn157.0022.292.5721.451.8376.7776.77951.17666.48----------------39.44--8.07--1.14--0.4249--0.5715---53.61------
CanBas Co Ltd (Parent)0.00-1.09bn9.10bn12.00--3.04-----64.47-64.470.00166.100.00----0.00-43.91-65.86-45.99-79.11-------1,094.10----0.00-------45.41------
Tsubota Laboratory Inc673.53m-641.32m9.23bn10.00--6.75--13.71-25.15-25.1526.4253.450.27112.0437.74---25.82---36.41--3.17---95.22--2.31-489.860.0788---29.45---811.14------
Linical Co Ltd12.31bn338.27m9.77bn759.0026.371.0811.410.79414.9814.98544.93364.600.6837--3.59--1.884.013.156.3330.7030.992.755.48----0.260350.10-1.671.70-66.32-9.86-10.184.56
AnGes Inc249.94m-6.35bn10.30bn145.00--0.3616--41.22-32.62-32.621.29124.450.00770.08624.771,723,752.00-19.47-28.50-23.06-33.1439.8539.42-2,540.59-6,726.820.9124--0.0139--128.13-24.1749.45--12.11--
KOEI CHEMICAL COMPANY, LIMITED19.43bn299.18m11.26bn387.0037.550.51494.820.579461.1761.173,971.904,460.940.49571.663.80--0.76593.150.9973.9427.1725.241.555.850.6907115.660.320743.884.441.19-56.72-20.82-3.2910.76
3-D Matrix Ltd3.74bn-1.06bn11.43bn108.00--18.08--3.06-14.90-14.9054.067.740.66530.46545.1934,630,130.00-18.91-57.69-23.28-77.3164.0440.76-28.43-205.342.33--0.8717--53.6358.87-29.09---7.69--
Medinet Co Ltd711.82m-1.40bn11.54bn98.00--2.07--16.21-6.00-6.003.0321.730.12411.343.787,263,510.00-24.31-21.05-25.48-22.4715.2528.75-196.06-135.4020.08--0.00--4.40-7.90-14.66---17.67--
Stella Pharma Corp269.49m-763.75m12.05bn46.00--5.07--44.73-24.63-24.638.7076.120.06610.05083.98---18.74-22.50-21.00-24.8380.63---283.40-488.655.52-379.390.2819--17.65--1.94---5.87--
Nano Mrna Co Ltd135.51m-780.00m12.11bn17.00--3.54--89.35-11.10-11.101.9348.610.02559.029.66---14.37-24.16-15.59-25.1781.8884.69-575.61-600.709.17--0.2448---32.98-22.8840.50------
ReproCell Inc2.43bn-31.42m12.53bn92.00--1.50165.115.16-0.3465-0.346528.3493.450.27885.415.60---0.3609-7.35-0.3932-8.0046.1939.83-1.29-27.1610.54-------17.8317.3989.71--13.27--
RaQualia Pharma Inc2.18bn-253.40m12.68bn67.00--2.11--5.82-11.72-11.72100.79277.210.2472.763.0332,526,720.00-2.872.13-3.182.2688.7088.49-11.635.323.53--0.40310.00-34.8520.62-144.74--0.0967--
Ohki Healthcare Holdings Co Ltd334.66bn2.21bn13.45bn576.005.960.46857.470.0402160.46160.4624,294.612,040.702.5613.334.74--1.631.857.078.425.146.160.63560.71780.8922--0.199313.929.925.301.281.51-5.345.92
Oncolys Biopharma Inc28.04m-1.98bn13.86bn34.00--7.86--494.17-107.77-107.771.5284.140.01270.000.1476824,647.10-89.46-45.75-101.52-51.86100.0060.46-7,058.44-233.668.82--0.1416---93.54-17.86-68.72--28.18--
Data as of Jun 10 2024. Currency figures normalised to 3-D Matrix Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

2.19%Per cent of shares held by top holders
HolderShares% Held
Heights Capital Management, Inc.as of 22 May 20241.40m1.76%
Simplex Asset Management Co., Ltd.as of 09 May 2024334.60k0.42%
Data from 31 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.